Palisade Bio (NASDAQ:PALI) and Curis (NASDAQ:CRIS) Head to Head Analysis

Palisade Bio (NASDAQ:PALI) and Curis (NASDAQ:CRIS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Analyst Recommendations

This is a summary of current recommendations and price targets for Palisade Bio and Curis, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palisade Bio	0	0	2	0	3.00
Curis	0	0	3	0	3.00

Palisade Bio presently has a consensus price target of $23.00, suggesting a potential upside of 1,454.05%. Curis has a consensus price target of $23.00, suggesting a potential upside of 570.55%. Given Palisade Bio’s higher possible upside, analysts clearly believe Palisade Bio is more favorable than Curis.

Institutional & Insider Ownership

11.8% of Palisade Bio shares are owned by institutional investors. Comparatively, 30.0% of Curis shares are owned by institutional investors. 3.3% of Palisade Bio shares are owned by company insiders. Comparatively, 5.7% of Curis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Palisade Bio and Curis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Palisade Bio	N/A	-148.51%	-115.16%
Curis	-443.35%	-923.37%	-78.35%

Risk and Volatility

Palisade Bio has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500. Comparatively, Curis has a beta of 3.42, meaning that its stock price is 242% more volatile than the S&P 500.

Earnings and Valuation

This table compares Palisade Bio and Curis”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palisade Bio	$250,000.00	16.37	-$12.30 million	($13.98)	-0.11
Curis	$10.02 million	2.90	-$47.41 million	($7.81)	-0.44

Palisade Bio has higher earnings, but lower revenue than Curis. Curis is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.

Summary

Curis beats Palisade Bio on 7 of the 13 factors compared between the two stocks.

About Palisade Bio

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.

About Curis

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company’s pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.